Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: the results of a pilot study

Cephalalgia. 2011 Apr;31(5):543-9. doi: 10.1177/0333102410392605. Epub 2011 Jan 7.

Abstract

Aims: This study was aimed to verify changes in the levels of hypothalamic neuropeptides in migraineurs under preventive treatment with amitryptiline and flunarizine. Thirty-nine migraine patients with a body mass index <25 kg/m(2) and without endocrinological or metabolic diseases were assigned to two treatment groups, one receiving amitryptiline, the other flunarizine, for 3 months. Orexin-A, orexin-B and neuropeptide-Y plasma levels were measured at the basal time, at the 1st, 2nd and 3rd months of preventive treatment.

Results: A statistically significant reduction in plasma orexin-A and orexin-B levels emerged in both groups. Conversely, plasma neuropeptide-Y levels were markedly increased, with the highest levels at the 2nd and 3rd months, in both patient groups. Orexin-A levels were also negatively correlated to weight gain in both groups during the treatment period.

Conclusions: These results suggest that changes in the levels of hypothalamic orexinergic peptides may contribute to body weight increase occurring in migraineurs during amitryptiline or flunarizine prophylactic treatment.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Amitriptyline / therapeutic use
  • Analgesics, Non-Narcotic / therapeutic use*
  • Female
  • Flunarizine / therapeutic use
  • Humans
  • Hypothalamus / drug effects
  • Hypothalamus / metabolism*
  • Male
  • Middle Aged
  • Migraine Disorders / blood
  • Migraine Disorders / prevention & control*
  • Neuropeptides / blood*
  • Pilot Projects
  • Radioimmunoassay
  • Weight Gain / drug effects*
  • Young Adult

Substances

  • Analgesics, Non-Narcotic
  • Neuropeptides
  • Amitriptyline
  • Flunarizine